Viridian Therapeutics (Nasdaq: VRDN) wins Lumvoa FDA nod and reports Q2 loss
Rhea-AI Filing Summary
Viridian Therapeutics reported second-quarter 2026 results and significant milestones. Lumvoa (veligrotug-vvze) was approved by the FDA for thyroid eye disease on June 26, 2026, ahead of its target PDUFA date, and was immediately launched in the U.S. Elegrobart remains on track for a planned BLA submission in the first quarter of 2027, while FcRn and TSHR programs are expected to meet 2026 development milestones. The company also completed a May 2026 convertible debt and equity financing with gross proceeds of $394 million.
For the three months ended June 30, 2026, Viridian generated $284 thousand in total revenues and incurred $126,552 thousand of operating expenses, resulting in a net loss of $127,119 thousand, compared with $100,735 thousand a year earlier. Cash, cash equivalents, and marketable securities were $981,530 thousand as of June 30, 2026, supporting total assets of $1,097,233 thousand, liabilities of $435,136 thousand, and stockholders’ equity of $662,097 thousand.
Positive
- Lumvoa received FDA approval for thyroid eye disease on June 26, 2026 and was immediately launched in the U.S., marking Viridian’s transition to a commercial-stage company.
- $394 million of gross proceeds from a May 2026 convertible debt and equity financing contributed to cash, cash equivalents, and marketable securities of $981,530 thousand as of June 30, 2026.
Negative
- Net loss increased to $127,119 thousand for the three months ended June 30, 2026, from $100,735 thousand a year earlier, as total operating expenses rose to $126,552 thousand.
Filing Explained
Viridian’s second-quarter report is complete: its common-stock loss was allocated across a weighted-average 107,884,104 shares, versus 81,593,463 a year earlier, producing a $1.05 per-share loss.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Total revenues: $284 thousand
Net loss: $127,119 thousand
Research and development expense: $71,577 thousand
+5 more
8 metrics
Total revenues
$284 thousand
Three months ended June 30, 2026
Net loss
$127,119 thousand
Three months ended June 30, 2026
Research and development expense
$71,577 thousand
Three months ended June 30, 2026
Selling, general and administrative expense
$54,975 thousand
Three months ended June 30, 2026
Cash, cash equivalents and marketable securities
$981,530 thousand
As of June 30, 2026
Gross proceeds from financing
$394 million
Convertible debt and equity financing completed in May 2026
Total liabilities
$435,136 thousand
As of June 30, 2026
Total stockholders’ equity
$662,097 thousand
As of June 30, 2026
Key Terms
thyroid eye disease (TED), BLA, FcRn, TSHR, +2 more
6 terms
thyroid eye disease (TED) medical
"Lumvoa™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED)"
An inflammatory condition in which the immune system attacks the tissues and muscles around the eyes, causing swelling, bulging, double vision, pain and, in severe cases, loss of sight. It matters to investors because its severity and prevalence drive demand for drugs, surgeries and diagnostics, influence healthcare spending and regulatory decisions, and can meaningfully affect revenue and valuations for companies developing or selling treatments—like a busted pipe creating urgent repair needs.
BLA regulatory
"Elegrobart ... on track for BLA submission Q1 2027"
FcRn medical
"Pipeline progress continues, with FcRn and TSHR program development milestones"
The neonatal Fc receptor (FCRN or FcRn) is a protein that controls how long antibodies and the blood protein albumin stay in circulation by protecting them from being broken down. For investors, therapies that block or harness FcRn can change a drug’s dosing, effectiveness and market appeal—either by lengthening beneficial antibodies for longer-lasting treatments or by reducing harmful antibodies in autoimmune disease—so progress in FcRn-targeted programs can materially affect a biotech’s commercial value.
TSHR medical
"Pipeline progress continues, with FcRn and TSHR program development milestones"
TSHR is the thyroid‑stimulating hormone receptor, a protein on thyroid cells that acts like a thermostat sensor: it detects the circulating hormone that tells the gland to make thyroid hormones and controls how strongly the gland responds. Investors watch TSHR because it is a common target for drugs and diagnostic tests, and changes involving the receptor — from new therapies to safety or regulatory findings — can affect the value of companies working on thyroid disease.
convertible debt and equity financing financial
"Completed convertible debt and equity financing in May 2026 with gross proceeds"
forward-looking statements regulatory
"This press release contains forward-looking statements."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Earnings Snapshot
Total revenues: $284 thousand · Guidance included
Three months ended June 30, 2026
Total revenues
$284 thousand
vs $75 thousand for the three months ended June 30, 2025
Net loss
$127,119 thousand
vs $100,735 thousand for the three months ended June 30, 2025
Research and development expense
$71,577 thousand
vs $86,626 thousand for the three months ended June 30, 2025
Selling, general and administrative expense
$54,975 thousand
vs $20,216 thousand for the three months ended June 30, 2025
Cash, cash equivalents and marketable securities
$981,530 thousand
vs $874,652 thousand as of December 31, 2025
Guidance
Viridian states that its cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart, are expected to fund its business plans through profitability, subject to the risks and uncertainties described in its risk disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What FDA approval did Viridian Therapeutics (VRDN) secure in 2026?
Viridian’s drug Lumvoa (veligrotug-vvze) received FDA approval for thyroid eye disease on June 26, 2026 and was immediately launched in the U.S. This represents the company’s first approved product and supports its move into commercial operations.
How did Viridian Therapeutics (VRDN) perform financially in Q2 2026?
For Q2 2026, Viridian reported total revenues of $284 thousand and a net loss of $127,119 thousand. Operating expenses were $126,552 thousand, reflecting ongoing R&D and commercial build-out, compared with a net loss of $100,735 thousand in the prior-year quarter.
What is the status of elegrobart at Viridian Therapeutics (VRDN)?
Elegrobart, a late-stage investigational therapy for TED, is on track for a planned BLA submission in Q1 2027. It is described as a potential first subcutaneous autoinjector treatment for thyroid eye disease designed for at-home self-administration.
What was Viridian Therapeutics’ (VRDN) cash position as of June 30, 2026?
As of June 30, 2026, Viridian reported cash, cash equivalents, and marketable securities of $981,530 thousand. This follows a May 2026 convertible debt and equity financing that generated $394 million in gross proceeds, strengthening the company’s liquidity profile.
How did Viridian Therapeutics’ (VRDN) operating expenses change year over year in Q2 2026?
In Q2 2026, research and development expense was $71,577 thousand, down from $86,626 thousand a year earlier, while selling, general and administrative expense rose to $54,975 thousand from $20,216 thousand, bringing total operating expenses to $126,552 thousand.
What funding outlook does Viridian Therapeutics (VRDN) describe?
Viridian states that its cash and anticipated commercial revenues from Lumvoa and, if approved, elegrobart are expected to be sufficient to fund its business plans through profitability, although this expectation is subject to numerous risks and uncertainties detailed in its risk disclosures.